Surgeons often care for patients with inflammatory bowel disease (IBD) who are receiving therapies that can include 5-ASA compounds, steroids, immunomodulators, and biologics. The goal of these agents is to suppress intestinal inflammation, ultimately improving the quality of life in patients afflicted with IBD. Traditionally, an acceptable therapeutic endpoint was the resolution of symptoms, defined as clinical remission. However, as a result of recent advances in therapy, clinicians can now strive to achieve more stringent endpoints, such as endoscopic or histologic remission. Many different classes of agents can be used, individually or in combination, to achieve mucosal healing.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.suc.2015.08.004 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Geographical and Socioeconomic Disparities in Substance and Opioid Use Disorders Among Inflammatory Bowel Disease Hospitalizations in the United States From the National Inpatient Sample.
J Clin Psychiatry
January 2025
Division of Gastrointestinal and Liver Diseases, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California.
We compared substance use disorder (SUD) prevalence among adult inflammatory bowel disease (IBD) hospitalizations with non-IBD controls from the 2016-2018 National Inpatient Sample, assessing correlations with demographics, socioeconomic status, geographic regions, depression, and anxiety. The primary aim focused on SUD, defined as substance abuse or dependence (: F10-F19) excluding unspecified use or remission, among hospitalizations documenting IBD (Crohn's disease or ulcerative colitis; : K50-51) as one admitting diagnosis (IBD-D). The prevalence of SUD among hospitalizations with and without IBD was compared.
View Article and Find Full Text PDFEmerging Connections Between Inflammatory Bowel Disease Subtypes and Sequential Changes in Total Serum Bilirubin.
Inflamm Bowel Dis
January 2025
GI Biopharma Inc, Westfield, NJ, USA.
GSDMB modulates intestinal epithelial homeostasis via regulating hyperactive unfolded protein response in Crohn's disease.
J Crohns Colitis
January 2025
Medical School of Nanjing University, Department of General Surgery, Jinling Hospital, Nanjing 210002, China.
Background: Impaired intestinal epithelial barrier has been considered to be associated with an increasing variety of gastrointestinal diseases, especially inflammatory bowel disease (IBD) encompassing Crohn's disease (CD) and ulcerative colitis (UC). We aimed to investigate the role of Gasdermin B (GSDMB) in modulating intestinal epithelial barrier integrity and proposed a promising therapeutic strategy.
Methods: GSDMB expression was evaluated in adult CD samples by molecular biology means and single-cell transcriptomes.
Helicobacter pylori infection is associated with significant elevations to fecal calprotectin, systemic inflammatory markers.
J Pediatr Gastroenterol Nutr
January 2025
Department of Pediatrics, Division of Pediatric Gastroenterology, SUNY Downstate Health Sciences University, Brooklyn, New York, USA.
Objectives: Fecal calprotectin (FC) is a marker commonly used in the diagnosis and follow-up of inflammatory bowel diseases (IBD). However, other gastrointestinal conditions, like H. pylori (HP) infection, can result in increased neutrophil activity as well.
View Article and Find Full Text PDFExamination of non-conventional dysplasias adjacent to colorectal adenocarcinoma in patients with IBD.
Pathol Oncol Res
January 2025
Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary.
Objective: Recently, several non-conventional variants of IBD-associated dysplasia have been described; however, their prevalence in Central-Eastern Europe is unknown. We aimed to perform a retrospective pilot study by re-evaluating several IBD-associated adenocarcinoma cases to survey the incidence of adjacent non-conventional dysplasia and validate that recent North American findings may apply to a European population.
Methods: Retrospectively, 28 randomly chosen cases of IBD-associated adenocarcinomas diagnosed between 2010 and 2022 were re-evaluated.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!